Midazolam pharmacokinetics following intravenous and buccal administration
about
Pediatric dental sedation: challenges and opportunitiesPropofol versus midazolam regarding their antioxidant activities.Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage.Management of prolonged seizures and status epilepticus in childhood: a systematic review.Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability.Nasal and buccal treatment of midazolam in epileptic seizures in pediatrics.Using arterial spin labeling perfusion MRI to explore how midazolam produces anterograde amnesia.Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Perioperative substitution of anti-epileptic drugs.Alternative delivery systems for agents to treat acute agitation: progress to date.Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.Combined strategies for enhancing the transdermal absorption of midazolam through human skin.Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).Development of benzodiazepines for out-of-hospital management of seizure emergencies.Pharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers
P2860
Q26783328-8CD2C9BB-D683-4251-8718-6C67499F3ECDQ32032727-BE08F3FE-7A95-43D0-AE1F-44667AAF8615Q34280244-007D89A6-997D-4BA7-846A-0C2EF4399312Q34971485-A802C27B-97C7-45E3-AA8B-1D536AE77590Q35804041-146161A6-F575-469A-97E7-488545018FE5Q36538823-64FC1518-A23B-4F93-954E-E077F4A979C8Q36751077-1BEB8179-E725-4C9D-8A69-64ADC98BB8ACQ37191624-2F7C0A33-EA2D-4831-AEFA-6C9ADE7466DDQ37695055-A8D08E2B-8C8B-4FD9-ACEB-3C6ED72B1F0BQ38133383-CFC61127-9136-45D7-8172-8942DC2C81CCQ38154852-CD3ED565-D1B3-431C-98EF-280CBF8E8235Q41834120-EF9CD41B-9BC2-4683-B466-3D64C2CEA8DAQ42925018-4116471E-B532-40EF-B8A0-7D5A1FD260BEQ45787444-6F57A04C-185E-4FF1-A477-F89902EAE59EQ47373267-21F65CE3-20D9-468F-BA20-985A77546062Q48333229-2713E04C-A24A-4FAF-AE61-743A460156F2Q49202202-959794E5-6972-4DC9-B796-51203363B7DBQ57413147-041B60E6-4076-4908-9B0E-BF73E3798498
P2860
Midazolam pharmacokinetics following intravenous and buccal administration
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Midazolam pharmacokinetics following intravenous and buccal administration
@ast
Midazolam pharmacokinetics following intravenous and buccal administration
@en
type
label
Midazolam pharmacokinetics following intravenous and buccal administration
@ast
Midazolam pharmacokinetics following intravenous and buccal administration
@en
prefLabel
Midazolam pharmacokinetics following intravenous and buccal administration
@ast
Midazolam pharmacokinetics following intravenous and buccal administration
@en
P2093
P2860
P1476
Midazolam pharmacokinetics following intravenous and buccal administration
@en
P2093
H W Striebel
R Schwagmeier
P2860
P304
P356
10.1046/J.1365-2125.1998.00781.X
P407
P577
1998-09-01T00:00:00Z